Pmv Pharmaceuticals Stock Today
| PMVP Stock | USD 1.43 0.02 1.42% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Pmv Pharmaceuticals is selling at 1.43 as of the 25th of February 2025; that is 1.42 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.41. Pmv Pharmaceuticals has over 59 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of September 2020 | Category Healthcare | Classification Health Care |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey. The company has 51.75 M outstanding shares of which 859.15 K shares are at this time shorted by private and institutional investors with about 5.18 trading days to cover. More on Pmv Pharmaceuticals
Moving against Pmv Stock
Pmv Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPmv Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pmv Pharmaceuticals' financial leverage. It provides some insight into what part of Pmv Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Pmv Pharmaceuticals (PMVP) is traded on NASDAQ Exchange in USA. It is located in 1 Research Way, Princeton, NJ, United States, 08540 and employs 63 people. Pmv Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 74 M. Pmv Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 51.75 M outstanding shares of which 859.15 K shares are at this time shorted by private and institutional investors with about 5.18 trading days to cover.
Pmv Pharmaceuticals currently holds about 277.43 M in cash with (55.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pmv Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationPmv Pharmaceuticals owns a total of 51.75 Million outstanding shares. The majority of Pmv Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pmv Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pmv Pharmaceuticals. Please pay attention to any change in the institutional holdings of Pmv Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pmv Ownership Details
Pmv Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-12-31 | 714.6 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 539.9 K | |
| Stonepine Capital Management Llc | 2024-12-31 | 535.8 K | |
| Citigroup Inc | 2024-12-31 | 514.9 K | |
| Two Sigma Investments Llc | 2024-12-31 | 507 K | |
| Peapod Lane Capital Llc | 2024-12-31 | 445.7 K | |
| Aldebaran Capital Llc | 2024-09-30 | 438.3 K | |
| Geode Capital Management, Llc | 2024-12-31 | 421.7 K | |
| M&t Bank Corp | 2024-12-31 | 399.5 K | |
| Orbimed Advisors, Llc | 2024-09-30 | 6.5 M | |
| Sio Capital Management, Llc | 2024-12-31 | 3.6 M |
Pmv Pharmaceuticals Historical Income Statement
Pmv Stock Against Markets
Pmv Pharmaceuticals Corporate Management
| Laura Leon | VP Operations | Profile | |
| Leila MD | Chief Officer | Profile | |
| Winston MBA | COO CFO | Profile | |
| Marc MD | Senior Affairs | Profile | |
| Tim Smith | Senior Relations | Profile | |
| Robert Ticktin | Head Counsel | Profile | |
| Deepika PharmD | Chief Officer | Profile |
Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.